Navigation Links
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/30/2009

PARIS, August 30 /PRNewswire-FirstCall/ --

- SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

Otamixaban is a first in class, rapid onset antithrombotic compound, acting as a direct selective inhibitor of factor Xa. Otamixaban is originating from Sanofi-aventis world-class thrombosis research portfolio and is currently in phase IIb clinical development phase.

"The data show that intermediate dosages of otamixaban may offer substantial reduction in major coronary complications in patients presenting with acute coronary syndrome, with bleeding rate comparable to current therapy," said Dr Marc Sabatine, MD, MPH, an Investigator in the TIMI Study Group and a cardiologist at Brigham and Women's Hospital, Harvard Medical School. "This research is addressing an important medical need, by potentially significantly improving outcomes of ACS patients undergoing PCI while simplifying the treatment pattern of the acute management phase of the disease." he added.

The double-blind phase I
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
2. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
3. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
8. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
9. Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth
10. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
11. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Akcea ... (NASDAQ: ISIS ), announced today that the ... Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for ... (FCS).  FCS is a rare genetic disease characterized ... pancreatitis. In a Phase 2 study published in ...
(Date:7/6/2015)... 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... that its board of directors has received a preliminary ... Simin Zhang , chairman of the board of directors ... an investment vehicle wholly owned by Mr. Zhang(" Neptunus ...
(Date:7/4/2015)... 2015 De toevoeging ... voor patiënten met niet-resectabele uitgezaaide colorectale kanker ... overleving in dat orgaan. Bij ... die alleen binnen de lever is uitgezaaid,werd ... (PFS) in de lever dankzij de toevoeging ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
(Date:7/5/2015)... ... 2015 , ... Doctors at the Swedish Cancer Institute in Seattle, Washington say ... the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just posted the full ... five mesothelioma patients treated with 25Gy of radiation over five days just prior to ...
(Date:7/4/2015)... ... ... hacker gains access to someone’s email account, it can lead to all sorts of trouble, ... FTC issued a scam alert about a social engineering scam which cons a target ... by the hacker. All they have to do is click for a password reset ...
(Date:7/3/2015)... ... July 03, 2015 , ... On June 30th SEO ... SEO training system called "Page One Engine" . The program, which has ... glowing reviews from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, ...
(Date:7/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national president recruitment for Regional Care, Inc. in Scottsbluff, Neb. ... Smith has recently placed more than 1,000 healthcare executives into organizations. , ...
(Date:7/3/2015)... St. Louis, MO (PRWEB) , ... July 03, 2015 , ... ... new responsive website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just ... for talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3
... University,s Slone Epidemiology Center have found that in a given ... than 4 million are taking them regularly (at least five ... findings appear in the August 31 issue of the journal ... the treatment of moderate to severe pain and are among ...
... 2008 Two new studies show that migraine headaches ... condition is frequently underdiagnosed. The studies, appearing in ... Society, examine the incidence among soldiers within 10 days ... , as well as U.S. Army officer trainees. ...
... Aug. 26 Buying travel insurance can be,complicated, ... the leading,online travel insurance comparison site, coverage is ... a world-class Customer Care Team,providing a level of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ), Providing access ...
... Stanford University School of Medicine are shedding light on how ... caused by an autoimmune attack on the pancreas, but the ... new study in mice implicates the immune signal interferon-alpha as ... sugar metabolism and make patients dependent on lifelong insulin injections. ...
... by government-sponsored programs, Census Bureau reports , , TUESDAY, ... without health insurance dropped by more than 1 million ... years, U.S. Census Bureau officials announced Tuesday. , The ... number of children getting health insurance through government-funded programs. ...
... heard on both the SIRIUS and XM services on SIRIUS, Hits 1 SIRIUS ... XM ... channel 24, NEW YORK, Aug. 26 ... Cancer (SU2C) Campaign to broadcast its "Just Stand Up" national,fundraising event live on ...
Cached Medicine News:Health News:Study examines use of opioids 2Health News:Army personnel show increased risk for migraine 2Health News:InsureMyTrip.com's Expert Customer Care Team Takes the Guesswork Out of Buying Travel Insurance 2Health News:Early trigger for type-1 diabetes found in mice, Stanford scientists report 2Health News:Early trigger for type-1 diabetes found in mice, Stanford scientists report 3Health News:Number of Uninsured Americans Drops 2Health News:Number of Uninsured Americans Drops 3Health News:SIRIUS XM Radio Joins Stand Up To Cancer Campaign with Live Broadcast of Star-Studded 'Just Stand Up' Fundraising Event on September 5 2Health News:SIRIUS XM Radio Joins Stand Up To Cancer Campaign with Live Broadcast of Star-Studded 'Just Stand Up' Fundraising Event on September 5 3Health News:SIRIUS XM Radio Joins Stand Up To Cancer Campaign with Live Broadcast of Star-Studded 'Just Stand Up' Fundraising Event on September 5 4
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: